La Jolla Pharmaceutical Company Receives Patent Allowance Covering Broad Range of Modified Pectin

AN DIEGO–(BUSINESS WIRE)–La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases today announced that the United States Patent and Trademark Office (“USPTO”) has issued a notice of allowance for patent application number 13/400,007 covering methods of treating chronic inflammation using modified pectin. Specifically, the patent, which expires in 2025 without taking into account patent term extension, provides proprietary protection for methods of treating chronic inflammation by administration of modified pectin with a molecular weight of 10-250 kilodaltons prepared by tangential flow filtration purification.

“Chronic inflammation is the hallmark of many serious conditions such as chronic kidney disease (CKD), non-alcoholic steatohepatitis (NASH) and heart disease,” said George Tidmarsh, MD, PhD, President and CEO at La Jolla. “We plan to leverage our patent position to solidify our company as the leader in helping patients suffering from chronic organ diseases using therapeutics derived from modified pectin.”“Purification of modified pectin is an essential component for biological activity and safety,” said James Rolke, Senior Director of Research and Development at La Jolla and an inventor on the allowed patent application. “These newly allowed claims broaden our proprietary position for the use of modified pectin as a treatment for organ disease that results from chronic inflammation including all useful molecular weights and dosage forms such as aqueous solutions.”

The Company’s intellectual property portfolio also includes several issued patents covering various modified pectin compositions and methods for preparing biologically active modified pectins. The Company also has pending patent applications directed toward additional modified pectin compositions and methods of use. These issued and pending patents provide or will provide proprietary coverage for GCS-100 and other modified pectin materials, including all modified pectins currently in clinical development. In addition, the company has filed additional patent applications based on newly obtained clinical and preclinical data.

About Pectin and GCS-100

Pectins are high molecular weight, complex polysaccharides that can be obtained from multiple sources (e.g., citrus, apple), all of which share a common basic structure comprising a block co-polymer of 1,4-linked galacturonic acid and 1-2-linked rhamnose with side branches of either 1,4-linked β-D-galactose or 1,5-α-linked L-arabinose. In addition, some portion of the galacturonic acid backbone can be esterified or exist as the uronic acid salt.

GCS-100, the company’s lead product candidate, is a modified pectin and is covered by the newly allowed claims and several other issued patents. GCS-100 has been administered to over 200 patients at doses as high as 800 mg/m2 weekly (about 20 mg/kg) in previous clinical studies in cancer patients. In addition, La Jolla recently announced it had met the primary endpoint for a phase 2 CKD study; a statistically significant increase in estimated glomerular filtration rate (eGFR) compared to placebo.

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company’s lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501, the Company’s second product candidate, is a natural peptide for the treatment of hepatorenal syndrome. LJPC-401, the Company’s third product candidate, is a natural peptide for the treatment of iron overload. For more information on the Company please visit http://www.ljpc.com.

Forward Looking Statement Safe Harbor

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause actual results to be materially different from these forward-looking statements. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”), all of which are available free of charge on the SEC’s web site http://www.sec.gov. These risks include, but are not limited to, risks relating to the development of GCS-100, LJPC-501 and LJPC-401, the success and timing of future preclinical and clinical studies of these compounds, and potential indications for which GCS-100, LJPC-501 and LJPC-401 may be developed. Subsequent written and oral forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in the Company’s reports filed with the SEC. The Company expressly disclaims any intent to update any forward-looking statements.

Contacts

La Jolla Pharmaceutical Company
George F. Tidmarsh, M.D., Ph.D.
President & Chief Executive Officer
858-207-4264
GTidmarsh@ljpc.com

or

Chester S. Zygmont, III
Director of Finance
858-207-4262
czygmont@ljpc.com